Biotech

All Articles

Cullinan, after $25M deal, return bispecific to Harbour

.Cullinan Therapy was made an impression on good enough along with Harbour BioMed's bispecific immun...

A closer consider Fierce Biotech's Tough 15

.In this week's incident of "The Top Pipe," our company are actually diving right into Fierce Biotec...

Lilly deals with stage 2 breakdown of tau-targeting med

.The confetti is still flying from Eli Lilly's event celebrating the commendation of Alzheimer's ill...

Biogen CMO Maha Radhakrishnan joins Sofinnova-- Chutes &amp Ladders

.Welcome to today's Chutes &amp Ladders, our roundup of notable leadership hirings, shootings as wel...

Lykos will ask FDA to reexamine its own selection complying with being rejected of MDMA therapy for trauma

.Complying with a poor showing for Lykos Rehabs' MDMA applicant for post-traumatic stress disorder a...

AN 2 one-halfs headcount, ceases period 3 test after data disappoint

.AN2 Therapeutics is actually rethinking its business in response to poor midphase records, promisin...

Merck spends $700M for bispecific, spying autoimmune opening as well as chance to test Amgen in cancer

.Merck &amp Co. is actually paying $700 million beforehand to test Amgen in a blood stream cancer ce...

Gilead pays out J&ampJ $320M to go out licensing package for seladelpar

.With Gilead Sciences almost an FDA selection for its own liver condition medicine seladelpar, the c...

' All hands on deck' at Lilly as peers target being overweight market

.Chief executive officer David Ricks may view the providers establishing outdoors tents at basecamp ...

Entero giving up personnel, leaving workplace and pausing R&ampD

.Bed mattress Liquidators has transformed Entero Therapeutics white colored as a slab. The lender or...